A study of various treatments on patients with advanced NSCLC with PD-L1 expression for at least 1 % of tumour cells has found that pembrolizumab treatment extended the OS compared to conventional docetaxel chemotherapy (12.7 vs 8.5 months) [186]; another study showed that in patients with advanced NSCLC and high PD-L1 expression on at least 50 % of tumour cells, median progression-free survival, overall survival, and response rates were significantly higher in patients receiving pembrolizumab than in those receiving docetaxel [187]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.